Vimarsana
Biggest News Aggregation in the World

Page 3 - Treatment Patterns News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Treatment Patterns. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Treatment Patterns Today - Breaking & Trending Today

New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL) - Vimarsana News

New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

Published: December 9, 2023

/PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced today that adult patients with relapsed/refractory (R/R) follicular lymphoma (FL)...

Source: prnewswire.com
Related Topics:
France GeneralUnited StatesSan DiegoCatherine ThieblemontHematol HemoterMariana Cota StirnerData From The Observational National Lymphocare StudyLymphoma Research FoundationEuropean Medicines AgencyDrug AdministrationUs IncExchange CommissionAmerican Society Of HematologyEuropean UnionParis UniversityAmerican SocietySaint Louis Assistance Publique Hopitaux De ParisBreakthrough Therapy DesignationFollicular LymphomaRelease SyndromeFull Prescribing InformationMedication GuideAllergan AestheticsPrivate Securities Litigation Reform ActQuarterly Reports
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma - Vimarsana News

Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Published: November 27, 2023

COPENHAGEN, Denmark--(BUSINESS WIRE)--Nov 27, 2023--

Source: valdostadailytimes.com
Related Topics:
United StatesSan DiegoNew JerseyAndrew CarlsenHematol HemoterDavid FreundelDrug AdministrationData From The Observational National Lymphocare StudyGenmab Us IncExchange CommissionGlobal Communications Corporate AffairsEuropean Medicines AgencyExposition Of The American Society HematologyAbbvie Biotechnology LtdCommittee For Medicinal Products Human UseEuropean UnionLymphoma Research FoundationBreakthrough Therapy DesignationMedicinal ProductsHuman UseChief Executive OfficerAnnual MeetingAmerican SocietyFollicular LymphomaRelease Syndrome
AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma - Vimarsana News

AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Published: November 27, 2023

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updates from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for...

Source: prnewswire.com
Related Topics:
United StatesMariana Cota StirnerUs IncExchange CommissionEuropean Medicines AgencyExposition Of The American Society HematologyLymphoma Research FoundationDrug AdministrationCommittee For Medicinal Products Human UseEuropean UnionData From The Observational National Lymphocare StudyBlood Cancer Press KitBreakthrough Therapy DesignationAnnual MeetingAmerican SocietyMedicinal ProductsHuman UseRelease SyndromeFull Prescribing InformationMedication GuideAllergan AestheticsPrivate Securities Litigation Reform ActQuarterly ReportsLymphoma ResearchAccessed November
More than 50% of CKD Patients with Anemia Receive No Treatment, Study Finds - Vimarsana News

More than 50% of CKD Patients with Anemia Receive No Treatment, Study Finds

Published: November 4, 2023

Analysis of nearly 15k patients with non-dialysis-dependent CKD and anemia provides insight into contemporary trends in management.

Source: hcplive.com
Related Topics:
United StatesRichard LafayetteAmerican Society Of Nephrology Kidney WeekStanford Glomerular Disease CenterOptum Electronic Health RecordsAmerican SocietyNephrology Kidney WeekKidney WeekTreatment PatternsPaper Presented
Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the - Vimarsana News

Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the

Published: November 2, 2023

Eighteen total abstracts accepted for presentation and publication, including results from four clinical trials evaluating epcoritamab in multiple treatment settings and patient populationsOral presentations highlighting new findings from a clinical trial of epcoritamab in patients with relapsed/refractory (R/R) dif...

Source: pharmiweb.com
Related Topics:
San DiegoUnited StatesNew JerseyUnited KingdomHematol HemoterDavid FreundelAndrew CarlsenJudith KlimovskyExchange CommissionLymphoma Research FoundationCompany AnnouncementOutcomes ResearchNational Comprehensive Cancer NetworkAbbvie Biotechnology LtdAmerican Society Of HematologyDiscovery ResearchExposition Of The American Society HematologyGlobal Communications Corporate AffairsData From The Observational National Lymphocare StudyEuropean UnionGenmab Us IncAnnual MeetingAmerican SocietyExecutive Vice PresidentChief Development Officer